Skip to main content
Premium Trial:

Request an Annual Quote

Avantra to Close on $7M Funding Round; Plans to Roll Out Biomarker-Detection Platform in Early 2011


This story originally ran on July 19.

By Adam Bonislawski

Courtagen Capital Group has launched a new company, Avantra Biosciences, using the assets of defunct biotech firm Decision Biomarkers that Courtagen purchased in bankruptcy court last December.

Avantra, which incorporated on Dec. 31, 2009, plans to close on a $7 million Series B funding round by the end of July and to begin selling its biomarker-detection platform in early 2011, Elizabeth Holland, spokesperson for Courtagen and Avantra, told ProteoMonitor.

The company will be selling the Avantra Biomarker Workstation – a multiplex, immunoassay-based biomarker detection platform developed by Decision Biomarkers, as well as a variety of assays created for the platform. The company presently has an angiogenesis panel and a cytokine panel for use with the Biomarker Workstation and plans to develop additional panels for use with the instrument.

"We will definitely be launching new panels, new assays. We're evaluating the market research right now," Holland said.

Avantra has seven employees, including several from Decision Biomarkers' R&D division, and is looking to hire a head of assay development, Holland said. The company is currently being run by Courtagen's management team.

Decision Biomarkers filed for Chapter 7 bankruptcy in US Bankruptcy Court in Boston on Dec. 22, 2009. In documents filed with the court, the company said it had assets of up to $50,000 and liabilities of greater than $1 million but less than $10 million. It listed 90 creditors, including Dana-Farber Cancer Institute, Fisher Scientific, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, and Perkin Elmer (PM 01/08/2010).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.